Literature DB >> 31548121

Oxytocin antagonism reverses the effects of high oestrogen levels and oxytocin on decidualization and cyclooxygenase activity in endometrial tissues.

Maria Sztachelska1, Donata Ponikwicka-Tyszko1, Gabriela Sokolowska2, Slawomir Anisimowicz3, Jan Czerniecki1, Weronika Lebiedzinska2, Monika Zbucka-Kretowska2, Marek Zygmunt4, Slawomir Wołczynski2, Piotr Pierzynski5.   

Abstract

RESEARCH QUESTION: What is the in-vitro effect of oxytocin receptor (OTR) antagonism on parameters of receptivity in human endometrial explants and endometrial stromal cell lines cultured in oestradiol-rich conditions mimicking ovarian stimulation?
DESIGN: Experimental in-vitro study on endometrial tissue explants collected by aspiration biopsy from 30 women undergoing fertility treatment and cultured endometrial tHESC cell line. The study examined the effects of high oestradiol, oxytocin and OTR antagonist on parameters of decidualization (cell viability and prolactin secretion) as well as cyclooxygenase-1/2 (COX-1/2) activity and prostaglandin F2α (PGF2α) secretion. Changes in expression of OXTR and COX-2 genes were examined using quantitative polymerase chain reaction (qPCR).
RESULTS: In experiments on cultured endometrial cell line, high oestradiol and oxytocin similarly limited the viability of cells. In cultured endometrial explants both also decreased the secretion of prolactin (a marker of decidualization) and augmented endometrial COX-2 activity and formation of PGF2α. Oxytocin antagonist atosiban was confirmed to reverse the above effects, both in the endometrial line and endometrial explants. Addition of atosiban to cultures acted analogously in experiments employing both oxytocin and high oestradiol.
CONCLUSIONS: Oxytocin antagonist reversed the effects of high oestradiol and oxytocin on parameters related to endometrial receptivity in conditions mimicking ovarian stimulation. This might point to a novel, endometrium-related mechanism to support embryo implantation achieved by the application of oxytocin antagonist prior to embryo transfer.
Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Decidualization; Embryo implantation; Endometrial receptivity; Ovarian stimulation; Oxytocin antagonist

Year:  2019        PMID: 31548121     DOI: 10.1016/j.rbmo.2019.06.002

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  5 in total

1.  Arg-Vasotocin Directly Activates Isotocin Receptors and Induces COX2 Expression in Ovoviviparous Guppies.

Authors:  Li Kang Lyu; Jian Shuang Li; Xiao Jie Wang; Yi Jia Yao; Ji Fang Li; Yun Li; Hai Shen Wen; Xin Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

2.  Comparison of frozen-thawed embryo transfer protocols in patients with previous cycle cancellation due to uterine peristalsis: a pilot study

Authors:  İlknur Selvi; Mehmet Erdem; Erhan Demirdağ; Funda Cevher; Cengiz Karakaya; Ahmet Erdem
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

3.  Comparison of lncRNA Expression in the Uterus between Periods of Embryo Implantation and Labor in Mice.

Authors:  Zijiao Zhao; Lu Chen; Maosheng Cao; Tong Chen; Yiqiu Huang; Nan Wang; Boqi Zhang; Fangxia Li; Kaimin Chen; Chenfeng Yuan; Chunjin Li; Xu Zhou
Journal:  Animals (Basel)       Date:  2022-02-08       Impact factor: 2.752

4.  Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy.

Authors:  Maria Sztachelska; Donata Ponikwicka-Tyszko; Lydia Martínez-Rodrigo; Piotr Bernaczyk; Ewelina Palak; Weronika Półchłopek; Tomasz Bielawski; Sławomir Wołczyński
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

Review 5.  Inflammation-Related Molecules at the Maternal-Fetal Interface during Pregnancy and in Pathologically Altered Endometrium.

Authors:  Wlodzimierz Sieg; Jolanta Kiewisz; Amira Podolak; Grzegorz Jakiel; Izabela Woclawek-Potocka; Jakub Lukaszuk; Krzysztof Lukaszuk
Journal:  Curr Issues Mol Biol       Date:  2022-08-23       Impact factor: 2.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.